FDA
-
-
-
-
-
-
-
elanco offers treatment options for new world screwworm in U.S. livestock
-
-
-
-
-
-
-
Elanco's Credelio Quattro™-CA1 (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) Receives First FDA Conditional Approval for Treatment of New World Screwworm in Dogs
-
-
-
-
-
-
-
Elanco gets FDA emergency authorization for screwworm treatment in dogs
-
-
-
-
-
-
-
Elanco Animal Health (ELAN) sells certain royalties and commercial milestones associated with XDEMVY to Blackstone Life Sciences and Blackstone Credit & Insurance for $295M Cash
-
-
-
-
-
-
-
INVESTOR ALERT: Berger Montague Advises Elanco Animal Health (NYSE: ELAN) Investors to Inquire About a Securities Fraud Class Action by December 6, 2024
-
-
-
-
-
-
-
Elanco Announces FDA Approval and Launch of Zenrelia™ (ilunocitinib tablets), Offering An Effective, Safe Solution in Canine Dermatology
-
-
-
-
-
-
-
ELAN INVESTIGATION NOTICE: BFA Law Alerts Investors that it is Investigating Elanco (NYSE: ELAN) for Securities Fraud; Investors who Suffered Losses are Urged to Contact the Firm
-
328,285 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

